Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis

Objective: To evaluate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a humanized anti-CD11/CD18 monoclonal antibody (Hu23F2G) in patients with multiple sclerosis. Methods: In this phase I uncontrolled dose escalation study, patients (n = 24) with primacy or secondary progressive multiple sclerosis received single intravenous infusions of Hu23F2G (0.01 to 4.0 mg/kg). Study parameters included safety, pharmacology, immunogenicity, and brain magnetic resonance imaging (MRT), Results: Hu23F2G had few adverse effects. but 2 cases of urinary tract infection and 2 cases of gingivitis did occur. Transient leukocytosis development in some subjects receiving greater than or equal to 1.0 mg/kg. The pharmacokinetic response was nonlinear, with the area under the curve increasing out of proportion to the increase in dose. The mean terminal half-life increased with dose and was 21.9 (SD, 12.8) hours at the 4.0 mg/kg dose. High saturation (>80%) of CD11/CD18 on circulating leukocytes was achieved with doses greater than or equal to 0.2 mg/kg, The duration of high leukocyte saturation was dose-dependent persisting for more than a week at the 4.0 mg/kg dose. A marked decrease in leukocyte migration in response to cutaneous inflammation was observed. Antibodies against Hu23F2G were not detected. The neurologic examinations were stable except for 1 subject who had worsening weakness associated with an infection. No significant changes were noted on brain MRI scans. Conclusions: Hu23F2G was tolerated at doses that achieved high degrees of leukocyte CD11/CD18 saturation with in vivo inhibition of leukocyte migration. Because this phase I study was not designed to determine the clinical efficacy of Hu23F2G, further studies are needed.